Woud, Wouter W.
Hesselink, Dennis A.
Hoogduijn, Martin J.
Baan, Carla C.
Boer, Karin
Article History
Received: 13 October 2022
Accepted: 16 December 2022
First Online: 20 December 2022
Competing interests
: In the last three years, D.A. Hesselink has received lecture fees and consulting fees from Astellas Pharma, Chiesi Pharma, Medincell, Novartis Pharma, Sangamo Therapeutics and Vifor Pharma. He has received grant support from Astellas Pharma and Chiesi Pharma [paid to his institution]. D.A. Hesselink does not have employment or stock ownership at any of these companies, and neither does he have patents or patent applications. All other authors declare to not have competing interests.